EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link: https://ebookbell.com/faq

We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.

For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Novel Sensitizing Agents For Therapeutic Antiegfr Antibodies Shi Hu

Name: Novel Sensitizing Agents For Therapeutic Antiegfr Antibodies Shi Hu
SKU: BELL-47283292
Price: 31.00 USD
Availability: InStock
Rating: 4.8 (54 reviews)

SKU: BELL-47283292

$ 31.00 ~~$ 45.00~~ (-31%)

4.8

54 reviews

Novel Sensitizing Agents For Therapeutic Antiegfr Antibodies Shi Hu instant download after payment.

Publisher: Academic Press

File Extension: PDF

File size: 7.49 MB

Pages: 255

Author: Shi Hu

ISBN: 9780128215845, 0128215844

Language: English

Year: 2022

Product desciption

Novel Sensitizing Agents For Therapeutic Antiegfr Antibodies Shi Hu by Shi Hu 9780128215845, 0128215844 instant download after payment.

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists.

Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance.